DT 330

Drug Profile

DT 330

Alternative Names: DT-330

Latest Information Update: 21 Jul 2016

Price : $50

At a glance

  • Originator University of Oklahoma
  • Developer DormaTarg
  • Class Antineoplastics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bladder cancer; Breast cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer

Most Recent Events

  • 21 Jul 2016 Preclinical trials in Prostate cancer in USA (Intraperitoneal)
  • 21 Jul 2016 Preclinical trials in Non-small cell lung cancer in USA (Intraperitoneal)
  • 21 Jul 2016 Preclinical trials in Malignant melanoma in USA (Intraperitoneal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top